Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial-Reference-Cited by-同舟云学术

Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial

Published:2018-05 Issue:5 Volume:19 Page:660-671
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Xu Rui-Hua,Muro Kei,Morita Satoshi,Iwasa Satoru,Han Sae Won,Wang Wei,Kotaka Masahito,Nakamura Masato,Ahn Joong Bae,Deng Yan-Hong,Kato Takeshi,Cho Sang-Hee,Ba Yi,Matsuoka Hiroshi,Lee Keun-Wook,Zhang Tao,Yamada Yasuhide,Sakamoto Junichi,Park Young Suk,Kim Tae Won

Publisher

Elsevier BV

Subject

Oncology

Reference29 articles.

1. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer;Piedbois;J Clin Oncol,1998

2. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study;Tournigand;J Clin Oncol,2004

3. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment;Grothey;J Clin Oncol,2004

4. Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer: a randomized clinical trial;Venook;JAMA,2017

5. Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil/leucovorin in patients with metastatic colorectal cancer: a pooled analysis of randomized trials;Arkenau;J Clin Oncol,2008

Cited by 122 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Irinotecan plus raltitrexed as second-line treatment in locally advanced or metastatic colorectal cancer patients: a prospective open-label, single-arm, multi-center, phase II study;BMC Cancer;2024-09-02

2. QUATTRO-II randomized trial: CAPOXIRI+bevacizumab vs. FOLFOXIRI+bevacizumab as first-line treatment in patients with mCRC;Med;2024-09

3. Zinc finger protein 180 induces an apoptotic phenotype by activating METTL14 transcriptional activity in colorectal cancer;Oncology Reports;2024-07-25

4. Comparison of systemic treatments for previously treated patients with unresectable colorectal liver metastases: a systematic review and network meta-analysis;Frontiers in Oncology;2024-07-10

5. Two cases of metastatic colorectal cancer with prolonged liver injury following capecitabine combination chemotherapy;BMJ Case Reports;2024-07